Xtl Biopharmaceuticals LTD. – American Depositary (NASDAQ:XTLB) Shorted Shares Decreased By 3.67%

June 16, 2018 - By Migdalia James

The stock of Xtl Biopharmaceuticals LTD. – American Depositary (NASDAQ:XTLB) registered a decrease of 3.67% in short interest. XTLB’s total short interest was 55,100 shares in June as published by FINRA. Its down 3.67% from 57,200 shares, reported previously. With 1,000 shares average volume, it will take short sellers 55 days to cover their XTLB’s short positions. The short interest to Xtl Biopharmaceuticals LTD. – American Depositary’s float is 1.29%.

The stock increased 3.16% or $0.06 during the last trading session, reaching $1.96. About 2,400 shares traded. XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) has declined 25.29% since June 16, 2017 and is downtrending. It has underperformed by 37.86% the S&P500.

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company has market cap of $9.74 million. The Company’s lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren??s syndrome. It currently has negative earnings. The firm also develops recombinant human erythropoietin for the treatment of multiple myeloma patients.

More news for XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) were recently published by: Equitiesfocus.com, which released: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact XTL Biopharmaceuticals (XTLB) Stock Price” on June 09, 2018. Prnewswire.com‘s article titled: “XTL Biopharmaceuticals Reports First Quarter 2018 Financial Results & Provides Update” and published on May 29, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: